Global Cardiac Marker Analyzer Market and Forecast, Impact of COVID-19, Product Analysis, Companies Business & Marketing Strategy, Major Deals
The global Cardiac Marker Analyzer market is predicted to reach US$ 4.75 Billion by 2027. Cardiac Marker analyzer represents a paradigm in diagnostics that provides high sensitivity and reliable information in minutes. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others. The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment.
Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others. It is ideally suited to both point of care testing and laboratory use. The factors such as increasing incidences of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public-private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are driving the growth of the market. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are some of the key factors hampering the growth of this market.
Impact of COVID-19 on Global Cardiac Marker Analyzer Market
The COVID–19 outbreak has become a global stress test. As the number of people infected with the virus continues to rise around the world, uncertainties about global economic growth increases. The COVID–19 disease has infected around 392 Million people worldwide. Globally the death toll has reached 5,745,435 according to the latest statistics from the Worldometers (as of February 5, 2022). The number is still growing, and the duration of the pandemic is still difficult to predict. The COVID–19 pandemic has restricted the growth of the Cardiac Marker Analyzer market, by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, the negative trend in the revenues of these businesses began to level off and stabilize prior to the third quarter of 2020. In the years to come, physicians are likely to witness an increase in influx of patients, hence driving the cardiac marker analyzer market.
Key Highlights of the Report
This 118 Page report with 11 Figures and 19 Tables has been studied from 8 View Points:
1. Cardiac Marker Analyzer Market & Forecast (2011 - 2027)
2. Impact of COVID-19 on Global Cardiac Marker Analyzer Market
3. Cardiac Marker Companies - Comparative Tests Analysis
4. Cardiac Marker Analyzer - Competitive Product Analysis
5. Cardiac Marker Analyzer - Specifications, Product Features & Benefits Analysis
6. Cardiac Marker Analyzer - Mergers, Acquisitions, Distribution, Partnership and Licensing Agreements
7. Emerging Markers Analysis
8. Companies Business & Marketing Strategy
The Cardiac Marker Analyzer Covered in the report are as follows:
1. Triage MeterPro Analyzer
2. The i-STAT System
3. Cobas h 232 POC System
4. Access 2 Immunoassay System
5. Stratus CS Analyzer
6. RAMP 200
7. RAMP Reader
8. i-chroma DUO Analyzer
9. DXpress Reader Analyzer
10. PATHFAST Analyzer
11. QL Care Analyzer
12. Meritas POC Analyzer
Cardiac Marker Analyzer - Key Company Analysis
1. Alere (Now Abbott)
2. Abbott Point of Care
3. Quidel Corporation
4. Roche
5. Beckman Coulter
6. Siemens Healthineers
7. Response Biomedical
8. Boditech
9. Lifesign
10. LSI Medience Corporation
11. CardioGenics Holdings Inc.
12. Trinity Biotech
Data Sources
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.
Research Methodologies
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.
Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others. It is ideally suited to both point of care testing and laboratory use. The factors such as increasing incidences of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public-private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are driving the growth of the market. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are some of the key factors hampering the growth of this market.
Impact of COVID-19 on Global Cardiac Marker Analyzer Market
The COVID–19 outbreak has become a global stress test. As the number of people infected with the virus continues to rise around the world, uncertainties about global economic growth increases. The COVID–19 disease has infected around 392 Million people worldwide. Globally the death toll has reached 5,745,435 according to the latest statistics from the Worldometers (as of February 5, 2022). The number is still growing, and the duration of the pandemic is still difficult to predict. The COVID–19 pandemic has restricted the growth of the Cardiac Marker Analyzer market, by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, the negative trend in the revenues of these businesses began to level off and stabilize prior to the third quarter of 2020. In the years to come, physicians are likely to witness an increase in influx of patients, hence driving the cardiac marker analyzer market.
Key Highlights of the Report
- In October 2017, Abbott completed its acquisition of Alere, concluding a deal first announced in February 2016.
- Abbott Point of Care Diagnostics sales is driven by continued adoption of Abbott's i-STAT handheld system.
- In 2020, Quidel’s cardiac immunoassay and specialized diagnostic solutions revenue declined, mainly due to lower demand during the COVID-19 pandemic.
- Cobas H232 POC system permits rapid and easy determination of cardiac blood markers such as Troponin T, NT-proBNP, D-dimer, CK-MB and myoglobin.
- A major focus of Response Biomedical development programs in cardiovascular testing has been clinical tests for the quantification of cardiovascular markers.
- In 2020, Abbott Point of Care Diagnostics sales declined, driven by lower demand during the COVID-19 pandemic. However, in 2021, Abbott Point of Care Diagnostics sales returned to pre-pandemic level.
- In March 2020, Siemens Healthineers announced market introduction of the teamplay digital health platform.
- CardioGenics is the only company to successfully deploy CL in a compact, fully automated POC platform.
- Siemens Healthineers launched the third phase of its Strategy 2025 with the beginning of fiscal year 2022.
- Trinity Biotech Point-of-Care revenues declined in 2020 by around 19.1% from the previous year figure.
This 118 Page report with 11 Figures and 19 Tables has been studied from 8 View Points:
1. Cardiac Marker Analyzer Market & Forecast (2011 - 2027)
2. Impact of COVID-19 on Global Cardiac Marker Analyzer Market
3. Cardiac Marker Companies - Comparative Tests Analysis
4. Cardiac Marker Analyzer - Competitive Product Analysis
5. Cardiac Marker Analyzer - Specifications, Product Features & Benefits Analysis
6. Cardiac Marker Analyzer - Mergers, Acquisitions, Distribution, Partnership and Licensing Agreements
7. Emerging Markers Analysis
8. Companies Business & Marketing Strategy
The Cardiac Marker Analyzer Covered in the report are as follows:
1. Triage MeterPro Analyzer
2. The i-STAT System
3. Cobas h 232 POC System
4. Access 2 Immunoassay System
5. Stratus CS Analyzer
6. RAMP 200
7. RAMP Reader
8. i-chroma DUO Analyzer
9. DXpress Reader Analyzer
10. PATHFAST Analyzer
11. QL Care Analyzer
12. Meritas POC Analyzer
Cardiac Marker Analyzer - Key Company Analysis
1. Alere (Now Abbott)
2. Abbott Point of Care
3. Quidel Corporation
4. Roche
5. Beckman Coulter
6. Siemens Healthineers
7. Response Biomedical
8. Boditech
9. Lifesign
10. LSI Medience Corporation
11. CardioGenics Holdings Inc.
12. Trinity Biotech
Data Sources
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.
Research Methodologies
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.
1. EXECUTIVE SUMMARY
2. IMPACT OF COVID-19 ON GLOBAL CARDIAC MARKER ANALYZER MARKET
3. GLOBAL CARDIAC MARKER ANALYZER MARKET & FORECAST (2011 - 2027)
4. CARDIAC MARKER COMPANIES - COMPARATIVE TESTS ANALYSIS
5. CARDIAC MARKER ANALYZER - COMPETITIVE PRODUCT ANALYSIS
6. ALERE (NOW ABBOTT)
6.1 Alere Triage
6.1.1 Alere Cardiology Net Sales (2010 - 2016)
7. QUIDEL CORPORATION
7.1 Quidel Triage system
7.1.1 Quidel Cardiac Immunoassay Net Sales (2017 - 2027)
8. ABBOTT POINT OF CARE
8.1 The i-STAT System
8.2 Abbott Laboratories Point of Care Diagnostics Sales (2011 - 2027)
9. ROCHE
9.1 Cobas h 232 POC System
10. BECKMAN COULTER
10.1 Access 2 Immunoassay System
11. SIEMENS HEALTHINEERS
11.1 Stratus CS Analyzer
11.2 Siemens Healthineers establishes global Digital Ecosystem to drive Digitalization of Healthcare
12. RESPONSE BIOMEDICAL
12.1 Cardiovascular Testing
12.1.1 Acute Myocardial Infarction (Heart Attack) Testing
12.1.2 Congestive Heart Failure (“CHF”) Testing
12.1.3 Thrombotic Disease Testing
12.2 RAMP Platform
12.2.1 RAMP
12.2.2 RAMP Reader
12.3 Response Cardiovascular Testing
12.3.1 RAMP TROPONIN I
12.3.2 RAMP NT-proBNP
12.3.3 RAMP MYOGLOBIN
12.3.4 RAMP CK-MB
12.3.5 RAMP D-DIMER
12.4 Response Biomedical Cardiovascular Net Sales (2010 - 2026)
13. BODITECH
13.1 i-chroma II Analyzer
14. LIFESIGN
14.1 DXpress Reader Analyzer
15. LSI MEDIENCE CORPORATION
15.1 PATHFAST Analyzer
16. CARDIOGENICS HOLDINGS INC.
16.1 QL Care Analyzer
17. TRINITY BIOTECH
17.1 Meritas POC Analyzer
17.2 Trinity Biotech Point of Care Diagnostics Sales (2010 - 2027)
18. MERGERS, ACQUISITIONS AND LICENSING AGREEMENTS
18.1 Alere Inc
18.2 CardioGenics
18.3 Response Biomedical
18.4 Abbott Laboratories
18.5 Siemens Healthineers
18.6 LSI Medience Corporation
18.7 Trinity Biotech
18.8 Quidel
19. EMERGING MARKERS
20. RESPONSE BIOMEDICAL - BUSINESS & MARKETING STRATEGY
20.1 Point
20.2 Point
20.3 Point
20.4 Point
21. ROCHE - BUSINESS & MARKETING STRATEGY
21.1 Point
21.2 Point
21.3 Point
22. BODITECH MED INC - BUSINESS AND MARKETING STRATEGY
22.1 Point
22.2 Point
23. SIEMENS HEALTHINEERS - BUSINESS AND MARKETING STRATEGY
23.1 Point
23.2 Point
23.3 Point
23.4 Point
23.5 Point
23.6 Point
23.7 Point
23.8 Point
2. IMPACT OF COVID-19 ON GLOBAL CARDIAC MARKER ANALYZER MARKET
3. GLOBAL CARDIAC MARKER ANALYZER MARKET & FORECAST (2011 - 2027)
4. CARDIAC MARKER COMPANIES - COMPARATIVE TESTS ANALYSIS
5. CARDIAC MARKER ANALYZER - COMPETITIVE PRODUCT ANALYSIS
6. ALERE (NOW ABBOTT)
6.1 Alere Triage
6.1.1 Alere Cardiology Net Sales (2010 - 2016)
7. QUIDEL CORPORATION
7.1 Quidel Triage system
7.1.1 Quidel Cardiac Immunoassay Net Sales (2017 - 2027)
8. ABBOTT POINT OF CARE
8.1 The i-STAT System
8.2 Abbott Laboratories Point of Care Diagnostics Sales (2011 - 2027)
9. ROCHE
9.1 Cobas h 232 POC System
10. BECKMAN COULTER
10.1 Access 2 Immunoassay System
11. SIEMENS HEALTHINEERS
11.1 Stratus CS Analyzer
11.2 Siemens Healthineers establishes global Digital Ecosystem to drive Digitalization of Healthcare
12. RESPONSE BIOMEDICAL
12.1 Cardiovascular Testing
12.1.1 Acute Myocardial Infarction (Heart Attack) Testing
12.1.2 Congestive Heart Failure (“CHF”) Testing
12.1.3 Thrombotic Disease Testing
12.2 RAMP Platform
12.2.1 RAMP
12.2.2 RAMP Reader
12.3 Response Cardiovascular Testing
12.3.1 RAMP TROPONIN I
12.3.2 RAMP NT-proBNP
12.3.3 RAMP MYOGLOBIN
12.3.4 RAMP CK-MB
12.3.5 RAMP D-DIMER
12.4 Response Biomedical Cardiovascular Net Sales (2010 - 2026)
13. BODITECH
13.1 i-chroma II Analyzer
14. LIFESIGN
14.1 DXpress Reader Analyzer
15. LSI MEDIENCE CORPORATION
15.1 PATHFAST Analyzer
16. CARDIOGENICS HOLDINGS INC.
16.1 QL Care Analyzer
17. TRINITY BIOTECH
17.1 Meritas POC Analyzer
17.2 Trinity Biotech Point of Care Diagnostics Sales (2010 - 2027)
18. MERGERS, ACQUISITIONS AND LICENSING AGREEMENTS
18.1 Alere Inc
18.2 CardioGenics
18.3 Response Biomedical
18.4 Abbott Laboratories
18.5 Siemens Healthineers
18.6 LSI Medience Corporation
18.7 Trinity Biotech
18.8 Quidel
19. EMERGING MARKERS
20. RESPONSE BIOMEDICAL - BUSINESS & MARKETING STRATEGY
20.1 Point
20.2 Point
20.3 Point
20.4 Point
21. ROCHE - BUSINESS & MARKETING STRATEGY
21.1 Point
21.2 Point
21.3 Point
22. BODITECH MED INC - BUSINESS AND MARKETING STRATEGY
22.1 Point
22.2 Point
23. SIEMENS HEALTHINEERS - BUSINESS AND MARKETING STRATEGY
23.1 Point
23.2 Point
23.3 Point
23.4 Point
23.5 Point
23.6 Point
23.7 Point
23.8 Point
LIST OF FIGURES:
Figure 3-1: Global - Cardiac Marker Analyzer Market (Million US$), 2011 - 2021
Figure 3-2: Global - Forecast for Cardiac Marker Analyzer Market (Million US$), 2022 - 2027
Figure 6-1: Global - Alere Cardiology Net Sales (Million US$), 2010 - 2016
Figure 7-1: Quidel - Cardiac Immunoassay Revenue (Million US$), 2017 – 2021
Figure 7-2: Quidel - Forecast for Cardiac Immunoassay Revenue (Million US$), 2022 - 2027
Figure 8-1: Global - Abbott Laboratories Point of Care Diagnostics Sales (Million US$), 2011 - 2021
Figure 8-2: Global - Forecast for Abbott Laboratories Point of Care Diagnostics Sales (Million US$), 2022 - 2027
Figure 12-1: Global - Response Biomedical Cardiovascular Product Sales (Million US$), 2010 - 2021
Figure 12-2: Global - Forecast for Response Biomedical Cardiovascular Product Sales (Million US$), 2022 - 2027
Figure 17-1: Global - Trinity Biotech Point of Care Diagnostics Sales (Million US$), 2010 - 2019
Figure 17-2: Global – Forecast for Trinity Biotech Point of Care Diagnostics Sales (Million US$), 2022 - 2027
Figure 3-1: Global - Cardiac Marker Analyzer Market (Million US$), 2011 - 2021
Figure 3-2: Global - Forecast for Cardiac Marker Analyzer Market (Million US$), 2022 - 2027
Figure 6-1: Global - Alere Cardiology Net Sales (Million US$), 2010 - 2016
Figure 7-1: Quidel - Cardiac Immunoassay Revenue (Million US$), 2017 – 2021
Figure 7-2: Quidel - Forecast for Cardiac Immunoassay Revenue (Million US$), 2022 - 2027
Figure 8-1: Global - Abbott Laboratories Point of Care Diagnostics Sales (Million US$), 2011 - 2021
Figure 8-2: Global - Forecast for Abbott Laboratories Point of Care Diagnostics Sales (Million US$), 2022 - 2027
Figure 12-1: Global - Response Biomedical Cardiovascular Product Sales (Million US$), 2010 - 2021
Figure 12-2: Global - Forecast for Response Biomedical Cardiovascular Product Sales (Million US$), 2022 - 2027
Figure 17-1: Global - Trinity Biotech Point of Care Diagnostics Sales (Million US$), 2010 - 2019
Figure 17-2: Global – Forecast for Trinity Biotech Point of Care Diagnostics Sales (Million US$), 2022 - 2027
LIST OF TABLES:
Table 4-1: Cardiac Marker Companies - Comparative Tests Analysis
Table 4-2: Cardiac Marker Companies - Comparative Tests Analysis
Table 4-3: Cardiac Marker Companies - Comparative Tests Analysis
Table 5-1: Cardiac Marker Analyzer - Competitive Product Analysis
Table 5-2: Cardiac Marker Analyzer - Competitive Product Analysis
Table 6-1: Alere - Triage Product Analytes
Table 15-1: PATHFAST - Technical Specifications
Table 18-1: Alere - Merger & Acquisition, 2007 - 2017
Table 18-2: Alere - Distribution/Partnership Agreement, 2008, 2016
Table 18-3: CardioGenics - Mergers & Acquisition, 2015
Table 18-4: CardioGenics - Licensing Agreement, 2012
Table 18-5: Response Biomedical - Distribution Agreement, 2011 - 2015
Table 18-6: Response Biomedical - Collaboration Deal, 2004 - 2015
Table 18-7: Abbott Laboratories - Merger & Acquisition, 2003, 2017, 2019
Table 18-8: Siemens Healthineers - Merger & Acquisition, 2017
Table 18-9: Siemens Healthineers - Strategic Partnership, 2017
Table 18-10: LSI Medience Corporation - Strategic Alliance, 2014
Table 18-11: Trinity Biotech - Merger & Acquisition, 2012
Table 18-12: Quidel Corporation - Merger & Acquisition, 2017
Table 4-1: Cardiac Marker Companies - Comparative Tests Analysis
Table 4-2: Cardiac Marker Companies - Comparative Tests Analysis
Table 4-3: Cardiac Marker Companies - Comparative Tests Analysis
Table 5-1: Cardiac Marker Analyzer - Competitive Product Analysis
Table 5-2: Cardiac Marker Analyzer - Competitive Product Analysis
Table 6-1: Alere - Triage Product Analytes
Table 15-1: PATHFAST - Technical Specifications
Table 18-1: Alere - Merger & Acquisition, 2007 - 2017
Table 18-2: Alere - Distribution/Partnership Agreement, 2008, 2016
Table 18-3: CardioGenics - Mergers & Acquisition, 2015
Table 18-4: CardioGenics - Licensing Agreement, 2012
Table 18-5: Response Biomedical - Distribution Agreement, 2011 - 2015
Table 18-6: Response Biomedical - Collaboration Deal, 2004 - 2015
Table 18-7: Abbott Laboratories - Merger & Acquisition, 2003, 2017, 2019
Table 18-8: Siemens Healthineers - Merger & Acquisition, 2017
Table 18-9: Siemens Healthineers - Strategic Partnership, 2017
Table 18-10: LSI Medience Corporation - Strategic Alliance, 2014
Table 18-11: Trinity Biotech - Merger & Acquisition, 2012
Table 18-12: Quidel Corporation - Merger & Acquisition, 2017
